Online citations, reference lists, and bibliographies.

Proton Pump Inhibitor-associated Pneumonia: Not A Breath Of Fresh Air After All?

Alexander L Fohl, R. Regal
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Over the past two decades, proton pump inhibitors (PPIs) have emerged as highly effective and relatively safe agents for the treatment of a variety of gastrointestinal disorders. Unfortunately, this desirable pharmacological profile has also contributed to superfluous and widespread use in both the inpatient and outpatient settings. While generally well-tolerated, research published over the last decade has associated these agents with increased risks of Clostridium difficile disease, fractures likely due to calcium malabsorption and both community-acquired (CAP) and hospital-acquired pneumonias (HAP). The mechanism behind PPI-associated pneumonia may be multifactorial, but is thought to stem from compromising the stomach's "acid mantle" against gastric colonization of acid-labile pathogenic bacteria which then may be aspirated. A secondary postulate is that PPIs, through their inhibition of extra-gastric H(+)/K(+)-ATPase enzymes, may reduce the acidity of the upper aerodigestive tract, thus resulting in increased bacterial colonization of the larynx, esophagus and lungs. To date, several retrospective case control studies have been published looking at the association between PPI use and CAP. Some studies found a temporal relationship between PPI exposure and the incidence of pneumonia, but only two could define a dose-response relationship. Furthermore, other studies found an inverse correlation between duration of PPI use and risk of CAP. In terms of HAP, we reviewed two retrospective cohort studies and one prospective study. One retrospective study in a medical ICU found no increased association of HAP in PPI-exposed patients compared to no acid-lowering therapy, while the other in cardiothoracic surgery patients showed a markedly increased risk compared to those receiving H(2)RAs. The one prospective study in ICU patients showed an increased risk of HAP with PPIs, but not with H(2)RAs. In conclusion, the current literature shows a slight trend toward an association between PPI use and pneumonia and an increased risk with PPIs over H(2)RAs, but the findings are not consistent across all studies. Larger controlled trials still need to be done to better identify the risk that PPIs impart towards patients contracting CAP or HAP. Until these are completed, we will have to continue to extrapolate across smaller controlled trials to predict the associated risks in our respective patient populations. In the interim, it appears prudent to limit the use of PPIs to situations where they are clinically indicated and, in such cases, use them at the lowest effective dose. In the case of prescribing for stress ulcer prophylaxis in ICU patients, perhaps H(2)RAs should be used as the preferred agents over PPIs.
This paper references
10.1136/gut.39.1.54
Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study.
J. Thorens (1996)
10.1111/j.1572-0241.2008.01975.x
Gastric Acid Suppression by Proton Pump Inhibitors as a Risk Factor for Clostridium Difficile-Associated Diarrhea in Hospitalized Patients
Mohammed A. Aseeri (2008)
10.1016/j.phrs.2008.09.016
Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety.
V. Savarino (2009)
10.1592/phco.28.8.951
Proton pump inhibitor use and risk of hip fractures in patients without major risk factors.
J. Kaye (2008)
10.1111/j.1572-0241.2000.03259.x
Overuse of acid-suppressive therapy in hospitalized patients
R. Nardino (2000)
10.1378/chest.08-1634
Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole vs ranitidine in cardiothoracic surgery patients.
T. Miano (2009)
10.1111/j.1365-2036.2006.02943.x
Review article: the clinical pharmacology of proton pump inhibitors
G. Sachs (2006)
10.1002/pds.1978
Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study.
S. Dublin (2010)
10.1001/JAMA.292.16.2012
Acid suppression and pneumonia: a clinical indication for rational prescribing.
J. Gregor (2004)
10.1097/EDE.0b013e3181b5f27d
Acid-suppressive Drugs and Community-acquired Pneumonia
L. Garcia Rodriguez (2009)
10.2146/AJHP060629
Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis.
R. Cadle (2007)
10.1016/j.drudis.2009.03.014
Proton pump inhibitors: actions and reactions.
J. Mullin (2009)
10.1111/j.1572-0241.2005.41956.x
Effect on Intragastric pH of a PPI with a Prolonged Plasma Half-Life: Comparison between Tenatoprazole and Esomeprazole on the Duration of Acid Suppression in Healthy Male Volunteers
R. Hunt (2005)
10.1590/S0034-72992006000100010
Estudo comparativo do pH e do volume salivar em indivíduos com laringofaringite crônica por doença do refluxo gastroesofágica antes e após o tratamento
C. Eckley (2006)
Proton pump inhibitors are an independent risk factor for an increased length of hospital stay in patients with Clostridium difficile infection.
Jagdish S. Nachnani (2008)
10.1053/j.gastro.2010.08.023
Safety of proton pump inhibitor exposure.
Y. Yang (2010)
10.1086/313954
Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults
J. Bartlett (2000)
10.1001/archinternmed.2011.199
Hypomagnesemia and proton pump inhibitors: below the tip of the iceberg.
T. Furlanetto (2011)
10.7326/0003-4819-149-6-200809160-00005
Proton-Pump Inhibitor Use and the Risk for Community-Acquired Pneumonia
Monika Sarkar (2008)
10.1001/ARCHINTE.167.9.950
Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study.
S. Gulmez (2007)
10.1111/j.1753-4887.2008.00015.x
Proton pump-inhibiting drugs, calcium homeostasis, and bone health.
M. Wright (2008)
10.1097/00003246-200205000-00026
Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity*
K. Zedtwitz-Liebenstein (2002)
10.7326/0003-4819-66-5-917
The absorption of calcium carbonate.
P. Ivanovich (1967)
10.2174/138920009787048392
The effect of proton pump inhibitors on the human microbiota.
B. J. Vesper (2009)
10.1097/00005537-200311000-00013
The H+/K+-ATPase (proton) pump is expressed in human laryngeal submucosal glands.
K. Altman (2003)
10.1016/0306-3623(94)00301-3
The effect of omeprazole on human natural killer cell activity.
C. Aybay (1995)
10.3109/08923979909052768
Effect of lansoprazole on human leukocyte function.
E. Capodicasa (1999)
10.1503/cmaj.092129
Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis
Chun-Sick Eom (2011)
10.1056/NEJM198507113130202
Calcium absorption and achlorhydria.
R. Recker (1985)
10.1001/JAMA.292.16.1955
Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs.
R. Laheij (2004)
10.1136/bmj.39406.449456.BE
Overprescribing proton pump inhibitors
I. Forgacs (2008)
10.1097/00124743-199704001-00012
Calcium and Vitamin D in the Prevention and Treatment of Osteoporosis
P. Orcel (1997)
10.1111/j.1365-2036.2008.03924.x
Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low‐endemicity, non‐outbreak hospital setting
B. Dalton (2009)
10.1016/j.otohns.2005.07.036
Proton Pump (H+/K+-ATPase) Expression in Human Laryngeal Seromucinous Glands
K. Altman (2005)
10.1016/j.jcrc.2007.11.003
Do proton-pump inhibitors increase the risk for nosocomial pneumonia in a medical intensive care unit?
M. Beaulieu (2008)
10.1016/S1808-8694(15)30035-5
Comparative study of salivary pH and volume in adults with chronic laryngopharyngitis by gastroesophageal reflux disease before and after treatment.
C. Eckley (2006)
10.1016/j.coph.2008.09.004
Proton pump inhibitors: the beginning of the end or the end of the beginning?
C. Scarpignato (2008)
10.1016/j.maturitas.2009.07.006
Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures.
Marc R Fournier (2009)
10.1345/aph.1G703
Acid Suppressive Therapy Use on an Inpatient Internal Medicine Service
C. Pham (2006)
10.1503/cmaj.1040876
Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies
S. Dial (2004)
10.1002/pds.1715
Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study.
P. Myles (2009)
10.1001/JAMA.296.24.2947
Long-term proton pump inhibitor therapy and risk of hip fracture.
Yu-Xiao Yang (2006)
Prevalent prescribing of proton pump inhibitors: Prudent or pernicious?
C. Pham (2006)
10.1086/511159
Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults
L. Mandell (2007)
10.1177/000348940711600311
Human Lung Mucous Glands Manifest Evidence of the H+/K+-ATPase Proton Pump
K. Altman (2007)
10.1053/j.ajkd.2009.11.019
A case series of proton pump inhibitor-induced hypomagnesemia.
E. Hoorn (2010)
10.1093/qjmed/hcn035
Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease.
M. N. Choudhry (2008)
10.5694/J.1326-5377.2009.TB02307.X
Proton-pump inhibitors and the risk of antibiotic use and hospitalisation for pneumonia.
E. Roughead (2009)
10.1007/S11894-008-0045-4
Potential adverse effects of proton pump inhibitors
G. Coté (2008)
10.1038/nrgastro.2009.125
Insights into the future of gastric acid suppression
K. Devault (2009)
10.1001/jama.2009.722
Acid-suppressive medication use and the risk for hospital-acquired pneumonia.
S. Herzig (2009)
10.1016/J.AMJMED.2005.02.007
Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial.
M. B. O'Connell (2005)
10.1097/00003246-199905000-00020
Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System.
M. Richards (1999)
10.1111/j.1365-2036.2010.04284.x
Meta‐analysis: proton pump inhibitor use and the risk of community‐acquired pneumonia
J. Johnstone (2010)
10.1111/j.0953-0673.1996.00359.x
Twenty‐four‐hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.
M. Hartmann (1996)



This paper is referenced by
10.1016/j.ydbio.2015.03.013
ATP4a is required for development and function of the Xenopus mucociliary epidermis - a potential model to study proton pump inhibitor-associated pneumonia.
Peter Walentek (2015)
10.1016/BS.SEDA.2015.05.008
Chapter 35 - Gastrointestinal Drugs
Karin E. Sandoval (2015)
10.7251/BII1301048R
Inhibitori protonske pumpe – primena i bezbednost
Јulijana Rašić (2013)
10.1007/978-1-4419-1623-5_31
Esophageal Reflux Disease and Its Complications
Missale Solomon (2012)
Effects of Ranitidine and Pantoprazole on Ventilator-Associated Pneumonia: A Randomized Double-Blind Clinical Trial
F. Bashar (2013)
10.1016/j.ejca.2015.11.015
'Tablet burden' in patients with metastatic breast cancer.
M. Milić (2016)
10.1016/j.jamcollsurg.2012.03.022
Perioperative risk of laparoscopic fundoplication: safer than previously reported-analysis of the American College of Surgeons National Surgical Quality Improvement Program 2005 to 2009.
S. Niebisch (2012)
10.20344/amp.10683
Inappropriate Prescribing to Elderly Patients in an Internal Medicine Ward.
Joana Urzal (2019)
10.5114/pm.2019.89585
Aspiration pneumonia – prophylaxis, diagnostics, and treatment
Anna Zasowska-Nowak (2019)
10.1093/cid/ciy671
A Case-Control Study: Clinical Characteristics of Nosocomial Bloodstream Infections Versus Non-bloodstream Infections of Acinetobacter spp.
Su Xin Xu (2018)
“ SHOULD I BE CONCERNED WITH THE LONG-TERM USE OF PROTON PUMP INHIBITOR THERAPY ? ”
T. Jayaraman (2016)
10.2174/1381612823666170622110046
"Stress" is 80 Years Old: From Hans Selye Original Paper in 1936 to Recent Advances in GI Ulceration.
Sándor Szabó (2017)
10.1007/978-3-319-90761-1_42-1
Gastroesophageal Reflux Disease and Complications
Adharsh Ravindran (2020)
10.1111/aas.13109
Stress ulcer prophylaxis in adult intensive care unit patients – a protocol for a systematic review
M. Barbateskovic (2018)
10.1111/jgs.15385
Proton‐Pump Inhibitors and Long‐Term Risk of Community‐Acquired Pneumonia in Older Adults
Jan Zirk-Sadowski (2018)
10.7759/cureus.6609
Reducing the Inappropriate Use of Proton Pump Inhibitors in an Internal Medicine Residency Clinic
Joshua Boster (2020)
The use of proton pump inhibitors in selected public hospital intensive care units in Johannesburg
Ntombiyethu Biyase (2016)
10.1111/aas.12099
Stress ulcer prophylaxis in the intensive care unit: is it indicated? A topical systematic review
M. Krag (2013)
10.1016/j.jpeds.2012.10.010
0.5 mg/kg versus 1 mg/kg of intravenous omeprazole for the prophylaxis of gastrointestinal bleeding in critically ill children: a randomized study.
M. Solana (2013)
10.1016/j.iccn.2014.07.002
Administration of enteral nutrition to adult patients in the prone position.
Dustin D Linn (2015)
10.1177/1559827616671505
GERD Management
J. Ayoub (2017)
10.1186/s13643-017-0509-4
Stress ulcer prophylaxis versus placebo or no prophylaxis in adult hospitalised acutely ill patients—protocol for a systematic review with meta-analysis and trial sequential analysis
S. Marker (2017)
10.1183/13993003.02509-2017
Risk factors for lung disease progression in children with cystic fibrosis
M. van Horck (2018)
Comparison of Histamine 2 Receptor Antagonists and Proton Pump Inhibitors on Infectious Complications in Critically Ill Patients
S. Park (2016)
10.12968/GASN.2013.11.6.25
H2RBs vs PPIs part 2: histamine-2 receptor blockers as a first-line agent for peptic ulcer disease prophylaxis
Ronnell Regidor (2013)
10.1007/s12603-017-0946-8
Drug prescription including interactions with anticancer treatments in the elderly: A global approach
Marie-Eve Rougé Bugat (2017)
10.1007/s40267-019-00671-3
Properly prescribed, proton pump inhibitors are largely safe, but precautions are needed to prevent potential problems, overuse and misuse
Adis Medical Writers (2019)
10.14735/amgh2018432
Proton pump inhibitors in the light of clinical studies and safety profile of long term use
Martin Ďuriček (2018)
10.1136/bmj.i5813
Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study
F. Othman (2016)
10.1007/s00464-014-3772-7
Magnetic sphincter augmentation and fundoplication for GERD in clinical practice: one-year results of a multicenter, prospective observational study
M. Riegler (2014)
10.1212/WNL.0b013e3181d55f8a
Traumatic brain injury
Emily Gilmore (2010)
10.1002/14651858.CD011969.pub2
Deprescribing versus continuation of chronic proton pump inhibitor use in adults.
Taline A Boghossian (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar